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Clinics and pathology 
Disease 
Found in plasma cell leukaemia, multiple myeloma, 
plasmacytoma and monoclonal gammopathy of 
unknown significance (MGUS). 
Phenotype/cell stem origin 
Malignant plasma cells have the phenotype of mature 
terminally differenciated B-cells; there origin may be a 
pluripotent stem cell. 
Epidemiology 
Poorly described before FISH, quite karyotypically 
undetectable: found initially in cell lines, it repr sents 
the second more frequent IgH associated 
rearrangement, after t(11;14); detected by interphase 
FISH or RT-PCR in 25% MM cell lines, 15-20% 
primary MM and 0-10% MGUS lines; might be 
frequent but karyotypically undetected. 
Clinics 
Found in MM cases with unfavorable prognosis, even 
in patients treated with high dose chemotherapy. 
Cytogenetics 
Cytogenetics morphological 
May be undetectable (telomere-telomere translocation). 
Cytogenetics molecular 




Hypodiploid karyotype and -13 / 13q- in major part of 
cases. 





c-FGFR3 (4p16.3) in normal cells: PAC 884J17 - Courtesy 
Mariano Rocchi,  Resources for Molecular Cytogenetics. 
Protein 
Member of the tyrosine-kinase FGF receptor family, 
contains an extracellular domain with Ig-like loops, a 
transmembrane domain, and intracellular tyrosine 
kinase domains; localisation: plasma membrane; 
tyrosine kinase receptor; role in signal transduction, 
activates multiple signaling pathways regulating cell 
proliferation and differentiation; constitutional point 
mutations resulting in ligand-independent activation, 
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MMSET (multiple myeloma SET 
domain), also kown as WHSC1 (Wolf-




90 kb, 25 exons, 5' - 3' centromeric orientation - 
complex alternative splicing. 
Protein 
136 KDa, 4 domains: PWWP domain (proline-
tryptophan-tryptophan-prolin motif), HMG box (high 
mobility group), PHD-type (plant-homeodomain) zinc 
finger domain and SET (suppressor of variegation 
enhancer of zeste and Trithorax) domain. One full 
length 1365 aa isoenzyme and 4 possible truncated 
variants. Transcription factor, ubiquitously express d 
but preferentially in growing embryonic tissues. 
Chromatin remodelling agent, regulates histones 
methylation. 
Constitutional deletion of one copy is responsible for 
Wolf-Hirschhorn syndrom by haplo-insufficiency. 




4p16.3 breakpoint in a 110 kb region between MMSET 
(centromeric) within the 5' introns, and FGFR3 
(telomeric). 14q32 breakpoint in the IgH switch region 
involving JH + constant region. 
Two fusions generated, FGFR3 brought under the 
influence of the Ig gene enhancer Ea on der(14); 
MMSET under the influence of enhancer Eµ on der(4). 
Both FGFR3 and MMSET genes are deregulated by the 
translocation and a IgH-MMSET fusion transcript, 
detectable by RT-PCR, is generated. 
Fusion protein 
Description 
No IgH-FGFR3 fusion protein, but promoter exchange 
between both partner genes; however, somatic 
mutations similar to what has been found in 
thanatophoric dwarfism have been identified in some 
cases; they may also contribute to abnormal FGFR3 
activation. According to the variable breakpoint inside 
MMSET gene, the translocation may generate either a 
full length MMSET protein or a NH2-terminal 
truncated one. 
Oncogenesis 
Overexpression and activation of FGFR3 provides an 
oncogenic signal enhancing cell proliferation and 
survival. The functional consequences of MMSET 
deregulation are not completely investigated. All 
t(4;14) positive cases express MMSET whereas 30% 
lack FGFR3 expression, sometimes correlated with loss
of der(14), which tends to demonstrate that MMSET 
dysregulation should be the crucial oncogenic event. 
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